A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer
Abstract
Pancreatic cancer (PC) represents an aggressive disease with median overall survival (OS) of less than 1 year in the front-line setting. FOLFIRINOX and gemcitabine and paclitaxel (GP) are standard of care options for these patients; however, optimal selection of therapy is challenging.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 24, 2023
- Source ID
- 10.1093/oncolo/oyad178
Entities
People
- Aatur D Singhi
- Alexa Schrock
- David Fabrizio
- Dexter Jin
- Ericka M Ebot
- Ethan Sokol
- Garrett M Frampton
- Jay Moore
- Jie He
- Justin Newberg
- Katherine T Lofgren
- Kuei-ting Chen
- Michael J. Pishvaian
- Neeru Bhardwaj
- Priti Hegde
- Russell Madison
- Zoe Fleischmann
Organizations
- Foundation Medicine
- Johns Hopkins University
- National Cancer Institute
- National Pancreas Foundation
- United States Department of Defense